Heart Test Labs Inc. (HTL) has raised about $12 million in its most recent funding round. The company is developing Myovista, an electrocardiography device, that it said could potentially fill the "diagnostic gap" in heart disease. HTL is currently vying for approval of Myovista in Europe. Read More
